Cristina Cardona Cardona Barreña

Ms. Cristina Cardona Cardona Barreña

Neurodegeneration and Ophthalmology, Universitätsklinikum Tübingen, Tübingen, Baden-Württemberg, Germany
+1
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
LMLuke S. Myers
Luke S. Myers
SCSarah G. Christian
Sarah G. Christian
SSSean Simpson
Sean Simpson
RSRenan Sper
Renan Sper
CTClint Taylor
Clint Taylor
SDScott V. Dindot
Scott V. Dindot
Angelman syndrome is a neurodevelopmental disorder characterized by severe motor and cognitive deficits. It is caused by the loss of the maternally inherited allele of the imprinted ubiquitin-protein ligase E3A ( UBE3A ) gene. Rodent models of Angelman syndrome do not fully recapitulate all the symptoms associated with the condition and are limited as a preclinical model for therapeutic development. Here, we show that pigs ( Sus scrofa ) with a maternally inherited deletion of UBE3A ( UBE3A -/+ ) have altered postnatal behaviors, impaired vocalizations, reduced brain growth, motor incoordination, and ataxia. Neonatal UBE3A -/+ pigs exhibited several symptoms observed in infants with Angelman syndrome, including hypotonia, suckling deficits, and failure to thrive. Collectively, these findings are consistent with the pathophysiology and developmental trajectory observed in individuals with Angelman syndrome. We anticipate that this pig model will advance our understanding of the pathophysiology of Angelman syndrome and be used as a preclinical large animal model for therapeutic development.

14 October 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LELina Maria Carmona Echeverria
Lina Maria Carmona Echeverria
AHAiman Haider
Aiman Haider
AFAlex Freeman
Alex Freeman
USUrszula Stopka-Farooqui
Urszula Stopka-Farooqui
ARAvi Rosenfeld
Avi Rosenfeld
HWHayley C. Whitaker
Hayley C. Whitaker
Gleason score 7 prostate cancer with a higher proportion of pattern 4 (G4) has been linked to genomic heterogeneity and poorer patient outcome. The current assessment of G4 proportion uses estimation by a pathologist, with a higher proportion of G4 more likely to trigger additional imaging and treatment over active surveillance. This estimation method has been shown to have inter-observer variability. Fifteen patients with Prostate Grade Group (GG) 2 (Gleason 3 + 4) and fifteen patients with GG3 (Gleason 4 + 3) disease were selected from the PROMIS study with 192 haematoxylin and eosin-stained slides scanned. Two experienced uropathologists assessed the maximum cancer core length (MCCL) and G4 proportion using the current standard method (visual estimation) followed by detailed digital manual annotation of each G4 area and measurement of MCCL (planimetric estimation) using freely available software by the same two experts. We aimed to compare visual estimation of G4 and MCCL to a pathologist-driven digital measurement. We show that the visual and digital MCCL measurement differs up to 2 mm in 76.6% (23/30) with a high degree of agreement between the two measurements; Visual gave a median MCCL of 10 ± 2.70 mm (IQR 4, range 5–15 mm) compared to digital of 9.88 ± 3.09 mm (IQR 3.82, range 5.01–15.7 mm) ( p = 0.64) The visual method for assessing G4 proportion over-estimates in all patients, compared to digital measurements [median 11.2% (IQR 38.75, range 4.7–17.9%) vs 30.4% (IQR 18.37, range 12.9–50.76%)]. The discordance was higher as the amount of G4 increased (Bias 18.71, CI 33.87–48.75, r 0.7, p < 0.0001). Further work on assessing actual G4 burden calibrated to clinical outcomes might lead to the use of differing G4 thresholds of significance if the visual estimation is used or by incorporating semi-automated methods for G4 burden measurement.

19 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
VUVijay Kumar Ulaganathan
Vijay Kumar Ulaganathan
LNLakshana Nagarajan
Lakshana Nagarajan
Cristina Cardona Cardona BarreñaCristina Cardona Cardona Barreña
Cristina Cardona Cardona Barreña
PRPadmapriya Ravichandran
Padmapriya Ravichandran
MBMarie Beil
Marie Beil
YJYasmin Jrade
Yasmin Jrade
Cholangiocarcinoma (CCA) is a cancer of the bile duct epithelium, which is increasingly associated with chronic inflammation and/or cholestasis. In recent years, fibroblast growth factor (FGF) signaling has gained substantial interest in CCA with three U.S. Food and Drug Administration (FDA)-approved drugs currently available for targeted inhibition of FGF receptors (FGFRs). FGF signaling is implicated in various aspects of CCA tumorigenesis, influencing immune responses and correlating with less favorable therapeutic outcomes. Despite some progress in our understanding of the genetic underpinnings of CCA over the past decade, the contribution of patient-intrinsic germline variations implicated in FGF/FGFR signaling had not been systematically explored. Here, we explore the hypothesis that the dual impact of germline variants pleiotropically associated with the FGFR signaling pathway acts both as signals promoting tumorigenesis (tumor-intrinsic) and as shields protecting tumors from targeted immune response (tumor-extrinsic). This dualistic behavior sheds insights into the intricate interplay between genetic predisposition and pleiotropic factors in CCA pathogenesis, potentially impacting the prognosis of targeted therapies and immune checkpoint blockade therapies.